Development and Validation of the American Heart Association's PREVENT Equations.

cardiovascular diseases heart failure kidney diseases models, cardiovascular risk assessment social determinants of health

Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
06 Feb 2024
Historique:
pubmed: 10 11 2023
medline: 10 11 2023
entrez: 10 11 2023
Statut: ppublish

Résumé

Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD. The derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets. Among 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763-0.809) in female and 0.757 (0.727-0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81-1.16) and 0.94 (0.81-1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD- and heart failure-specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004-0.005] and 0.005 [0.004-0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84-1.20] versus 1.39 [1.14-1.65]; PREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.

Sections du résumé

BACKGROUND UNASSIGNED
Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD.
METHODS UNASSIGNED
The derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets.
RESULTS UNASSIGNED
Among 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763-0.809) in female and 0.757 (0.727-0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81-1.16) and 0.94 (0.81-1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD- and heart failure-specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004-0.005] and 0.005 [0.004-0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84-1.20] versus 1.39 [1.14-1.65];
CONCLUSIONS UNASSIGNED
PREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.

Identifiants

pubmed: 37947085
doi: 10.1161/CIRCULATIONAHA.123.067626
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

430-449

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK100446
Pays : United States

Auteurs

Sadiya S Khan (SS)

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.K.).

Kunihiro Matsushita (K)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).

Yingying Sang (Y)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).
Department of Population Health, New York University Grossman School of Medicine, New York, NY (Y.S., S.H.B., J.C.).

Shoshana H Ballew (SH)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).
Department of Population Health, New York University Grossman School of Medicine, New York, NY (Y.S., S.H.B., J.C.).

Morgan E Grams (ME)

Department of Medicine, Division of Precision Medicine, New York University Grossman School of Medicine, New York, NY (M.E.G., A.S.).

Aditya Surapaneni (A)

Department of Medicine, Division of Precision Medicine, New York University Grossman School of Medicine, New York, NY (M.E.G., A.S.).

Michael J Blaha (MJ)

Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Baltimore, MD (M.J.B.).

April P Carson (AP)

University of Mississippi Medical Center, Jackson (A.P.C.).

Alexander R Chang (AR)

Departments of Nephrology and Population Health Sciences, Geisinger Health, Danville, PA (A.R.C.).

Elizabeth Ciemins (E)

AMGA (American Medical Group Association), Alexandria, VA (E.C.).

Alan S Go (AS)

Division of Research, Kaiser Permanente Northern California, Oakland; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA; Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco; Department of Medicine (Nephrology), Stanford University School of Medicine, Palo Alto, CA (A.S,G.).

Orlando M Gutierrez (OM)

Departments of Epidemiology and Medicine, University of Alabama at Birmingham (O.M.G.).

Shih-Jen Hwang (SJ)

National Heart, Lung, and Blood Institute, Framingham, MA (S.-J.H.).

Simerjot K Jassal (SK)

Division of General Internal Medicine, University of California, San Diego and VA San Diego Healthcare, CA (S.K.J.).

Csaba P Kovesdy (CP)

Medicine-Nephrology, Memphis Veterans Affairs Medical Center and University of Tennessee Health Science Center, Memphis (C.P.K.).

Donald M Lloyd-Jones (DM)

Department of Preventive Medicine, Northwestern University, Chicago, IL (D.M.L.-J.).

Michael G Shlipak (MG)

Department of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, and San Francisco VA Medical Center (M.G.S.).

Latha P Palaniappan (LP)

Center for Asian Health Research and Education and the Department of Medicine, Stanford University School of Medicine, CA (L.P.P.).

Laurence Sperling (L)

Department of Cardiology, Emory University, Atlanta, GA (L.S.).

Salim S Virani (SS)

Department of Medicine, The Aga Khan University, Karachi, Pakistan; Texas Heart Institute and Baylor College of Medicine, Houston (S.S.V.).

Katherine Tuttle (K)

Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA; Kidney Research Institute and Institute of Translational Health Sciences, University of Washington, Seattle (K.T.).

Ian J Neeland (IJ)

UH Center for Cardiovascular Prevention, Translational Science Unit, Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA), Harrington Heart and Vascular Institute, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, OH (I.J.N.).

Sheryl L Chow (SL)

Department of Pharmacy Practice and Administration, College of Pharmacy, Western University of Health Sciences, Pomona, CA (S.L.C.).

Janani Rangaswami (J)

Washington DC VA Medical Center and George Washington University School of Medicine (J.R.).

Michael J Pencina (MJ)

Department of Biostatistics, Duke University Medical Center, Durham, NC (M.J.P.).

Chiadi E Ndumele (CE)

Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD (C.E.N.).

Josef Coresh (J)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).
Department of Population Health, New York University Grossman School of Medicine, New York, NY (Y.S., S.H.B., J.C.).

Classifications MeSH